Cystinosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Cystinosis is a systemic disease where
cystine crystals accumulate in all body cells and tissues and is the most
common genetic cause of renal Fanconi syndrome in children. It has 3 major
clinical presentations depending on the severity of mutations affecting the
CTNS gene: the infantile nephropathic form, the juvenile nephropathic form, and
the ocular non-nephropathic form. It is a lysosomal storage disorder caused by
mutations in the CTNS gene, encoding for the carrier protein cystinosin, which
transports cystine out of the lysosomal compartment. Defective cystinosin
function results in intra-lysosomal cystine accumulation in all body cells and
organs. The kidneys start affected during the first year of life through
proximal tubular damage followed by progressive glomerular damage and end-stage
renal failure during mid-childhood if not treated. Other affected organs
include the eyes, thyroid, pancreas, gonads, muscles and CNS. Leucocyte cystine
assay is the cornerstone for diagnosis and therapeutic disease monitoring.
- The incidence of Cystinosis ranges from 1 to 2 cases in every
150,000 live births in the USA.
Thelansis’s “Cystinosis Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Cystinosis
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Cystinosis across 8 MM market from the centre of Excellence/ Public/ Private
hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Cystinosis Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment